Canada French. New Zealand English. Brazil Portuguese. France French. Hungary Hungarian. Australia English. Netherlands Dutch. Korea Korean. Search Submit. Advil Tablets.
Advil Dual Action. Combining Medications. Pre-existing Health Conditions. Relief Finder. Aliskiren; Amlodipine: Moderate NSAIDs may attenuate the antihypertensive effects of aliskiren by inhibiting the synthesis of vasodilatory prostaglandins. Among NSAIDs, indomethacin, naproxen, and piroxicam may have the greatest pressor effect, while the effects of sulindac and nabumetone may be significantly less. In patients who are elderly, volume-depleted including those on diuretic therapy , or with compromised renal function who are being treated with NSAIDs, coadministration of angiotensin II receptor antagonists may result in further deterioration of renal function, including acute renal failure.
Moderate NSAIDs may attenuate the antihypertensive effects of aliskiren by inhibiting the synthesis of vasodilatory prostaglandins. Alpha-blockers: Moderate If nonsteroidal anti-inflammatory drugs NSAIDs and an antihypertensive drug are concurrently used, carefully monitor the patient for signs and symptoms of renal insufficiency and blood pressure control.
Alteplase: Moderate NSAIDs can cause GI bleeding, inhibit platelet aggregation, prolong bleeding time; these pharmacodynamic effects may be increased when administered to patients receiving thrombolytic agents. Patients receiving these drugs concurrently should be monitored closely for bleeding. Altretamine: Major Altretamine causes mild to moderate dose-related myelosuppression. Due to the thrombocytopenic effects of altretamine, an additive risk of bleeding may be seen in patients receiving concomitant NSAIDs.
Patients receiving concurrent NSAIDs should be monitored closely for symptoms of active or occult gastrointestinal bleeding.
While NSAIDs appear to suppress microglial activity, which in turn may slow inflammatory neurodegenerative processes important for the progression of Alzheimer's disease AD , there are no clinical data at this time to suggest that NSAIDs alone or as combined therapy with AD agents result in synergistic effects in AD. Amikacin: Moderate It is possible that additive nephrotoxicity may occur in patients who receive nonsteroidal antiinflammatory drugs NSAIDs concurrently with other nephrotoxic agents, such as amikacin.
NSAIDS have been associated with an inhibition of prostaglandin synthesis, which may result in reduced renal blood flow leading to renal insufficiency and increases in blood pressure that are often accompanied by peripheral edema and weight gain.
If an NSAID and a diuretic are used concurrently, carefully monitor the patient for signs and symptoms of decreased renal function and diuretic efficacy. Aminolevulinic Acid: Moderate Agents that inhibit prostaglandin synthesis such as nonsteroidal antiinflammatory drugs NSAIDs , could decrease the efficacy of photosensitizing agents used in photodynamic therapy.
Aminosalicylate sodium, Aminosalicylic acid: Major Concomitant use of analgesic doses of aspirin with ibuprofen is generally not recommended due to the increased risk of bleeding, including GI bleeding.
Caution is recommended when administering amiodarone with CYP2C9 substrates including ibuprofen. The metabolism of ibuprofen may be decreased. Amlodipine; Benazepril: Moderate In the low-renin or volume-dependent hypertensive patient, prostaglandins play an important role in the hypotensive effects of ACE inhibitors. In patients who are elderly, volume-depleted including those on diuretic therapy , or with compromised renal function who are being treated with NSAIDs, the coadministration of ACE inhibitors may result in a further deterioration of renal function, including acute renal failure.
The potential clinical effects of selective or preferential COX-2 inhibitors are not known. Mean arterial blood pressure increased 3 mmHg in patients receiving ACE inhibitor benazepril 10 to 40 mg daily for 4 weeks with rofecoxib 25 mg once daily compared to the ACE inhibitor regimen alone. Amphotericin B cholesteryl sulfate complex ABCD : Moderate Concurrent use of amphotericin B and other nephrotoxic medications, including nonsteroidal antiinflammatory drugs NSAIDs , may enhance the potential for drug-induced renal toxicity.
Monitor renal function carefully during concurrent therapy. Amphotericin B dosage reduction may be necessary if renal impairment occurs. Amphotericin B liposomal LAmB : Moderate Concurrent use of amphotericin B and other nephrotoxic medications, including nonsteroidal antiinflammatory drugs NSAIDs , may enhance the potential for drug-induced renal toxicity.
Amphotericin B: Moderate Concurrent use of amphotericin B and other nephrotoxic medications, including nonsteroidal antiinflammatory drugs NSAIDs , may enhance the potential for drug-induced renal toxicity.
The manufacturer of clopidogrel advises that caution be used when used in combination with NSAIDs as an increase in occult GI blood loss occurred when clopidogrel was used concomitantly with naproxen Angiotensin II receptor antagonists: Moderate Nonsteroidal antiinflammatory drugs NSAIDs including selective COX-2 inhibitors may alter the response to Angiotensin II receptor blockers due to inhibition of vasodilatory prostaglandins.
Angiotensin-converting enzyme inhibitors: Moderate In the low-renin or volume-dependent hypertensive patient, prostaglandins play an important role in the hypotensive effects of ACE inhibitors.
Antithrombin III: Moderate An additive risk of bleeding may be seen in patients receiving anticoagulants in combination with other agents known to increase the risk of bleeding such as nonsteroidal antiinflammatory drugs NSAIDs. Monitor clinical and laboratory response closely during concurrent use.
Antithymocyte Globulin: Moderate An increased risk of bleeding may occur when NSAIDs are used with agents that cause clinically significant thrombocytopenia, such as antithymocyte globulin. Patients receiving these drugs together should be monitored closely for bleeding. Apixaban: Major An additive risk of bleeding may be seen in patients receiving anticoagulants in combination with other agents known to increase the risk of bleeding such as nonsteroidal antiinflammatory drugs NSAIDs.
Aprepitant, Fosaprepitant: Minor Use caution if ibuprofen and aprepitant are used concurrently and monitor for a possible decrease in the efficacy of ibuprofen. After administration, fosaprepitant is rapidly converted to aprepitant and shares the same drug interactions. The effects of aprepitant on tolbutamide were not considered significant. Aprotinin: Moderate The manufacturer recommends using aprotinin cautiously in patients that are receiving drugs that can affect renal function, such as NSAIDs, as the risk of renal impairment may be increased.
Argatroban: Moderate An additive risk of bleeding may be seen in patients receiving anticoagulants in combination with other agents known to increase the risk of bleeding such as nonsteroidal antiinflammatory drugs NSAIDs. Arsenic Trioxide: Major An increased risk of bleeding may occur when NSAIDs, such as ibuprofen, are used with agents that cause clinically significant thrombocytopenia. Notable interactions may occur with myelosuppressive antineoplastic agents. Patients receiving ibuprofen concurrently with antineoplastic agents should be monitored closely for bleeding.
Aspirin, ASA: Major Concomitant use of analgesic doses of aspirin with ibuprofen is generally not recommended due to the increased risk of bleeding, including GI bleeding. Aspirin, ASA; Butalbital; Caffeine: Major Concomitant use of analgesic doses of aspirin with ibuprofen is generally not recommended due to the increased risk of bleeding, including GI bleeding.
Aspirin, ASA; Butalbital; Caffeine; Codeine: Major Concomitant use of analgesic doses of aspirin with ibuprofen is generally not recommended due to the increased risk of bleeding, including GI bleeding.
Aspirin, ASA; Caffeine: Major Concomitant use of analgesic doses of aspirin with ibuprofen is generally not recommended due to the increased risk of bleeding, including GI bleeding. Aspirin, ASA; Caffeine; Dihydrocodeine: Major Concomitant use of analgesic doses of aspirin with ibuprofen is generally not recommended due to the increased risk of bleeding, including GI bleeding. Aspirin, ASA; Caffeine; Orphenadrine: Major Concomitant use of analgesic doses of aspirin with ibuprofen is generally not recommended due to the increased risk of bleeding, including GI bleeding.
Aspirin, ASA; Carisoprodol: Major Concomitant use of analgesic doses of aspirin with ibuprofen is generally not recommended due to the increased risk of bleeding, including GI bleeding.
Aspirin, ASA; Carisoprodol; Codeine: Major Concomitant use of analgesic doses of aspirin with ibuprofen is generally not recommended due to the increased risk of bleeding, including GI bleeding. Aspirin, ASA; Citric Acid; Sodium Bicarbonate: Major Concomitant use of analgesic doses of aspirin with ibuprofen is generally not recommended due to the increased risk of bleeding, including GI bleeding.
Aspirin, ASA; Dipyridamole: Major Concomitant use of analgesic doses of aspirin with ibuprofen is generally not recommended due to the increased risk of bleeding, including GI bleeding. The manufacturer of clopidogrel advises that caution be used when used in combination with NSAIDs as an increase in occult GI blood loss occurred when clopidogrel was used concomitantly with naproxen Aspirin, ASA; Omeprazole: Major Concomitant use of analgesic doses of aspirin with ibuprofen is generally not recommended due to the increased risk of bleeding, including GI bleeding.
Aspirin, ASA; Oxycodone: Major Concomitant use of analgesic doses of aspirin with ibuprofen is generally not recommended due to the increased risk of bleeding, including GI bleeding. Aspirin, ASA; Pravastatin: Major Concomitant use of analgesic doses of aspirin with ibuprofen is generally not recommended due to the increased risk of bleeding, including GI bleeding. Atenolol: Moderate If nonsteroidal anti-inflammatory drugs NSAIDs and an antihypertensive drug are concurrently used, carefully monitor the patient for signs and symptoms of renal insufficiency and blood pressure control.
Atenolol; Chlorthalidone: Moderate If nonsteroidal anti-inflammatory drugs NSAIDs and an antihypertensive drug are concurrently used, carefully monitor the patient for signs and symptoms of renal insufficiency and blood pressure control. Atropine; Benzoic Acid; Hyoscyamine; Methenamine; Methylene Blue; Phenyl Salicylate: Major Concomitant use of analgesic doses of aspirin with ibuprofen is generally not recommended due to the increased risk of bleeding, including GI bleeding.
Azathioprine: Moderate NSAIDs should be used with caution in patients receiving immunosuppressives as they may mask fever, pain, swelling and other signs and symptoms of an infection. Azelastine; Fluticasone: Moderate Although some patients may need to be given corticosteroids and NSAIDs concomitantly, which can be done successfully for short periods of time without sequelae, prolonged concomitant administration should be avoided.
Corticosteroids can have profound effects on sodium-potassium balance; NSAIDs also can affect sodium and fluid balance. Monitor serum potassium concentrations; potassium supplementation may be necessary. In addition, NSAIDs may mask fever, pain, swelling and other signs and symptoms of an infection; use NSAIDs with caution in patients receiving immunosuppressant dosages of corticosteroids.
The Beers criteria recommends that this drug combination be avoided in older adults; if coadministration cannot be avoided, provide gastrointestinal protection. Bacitracin: Major Avoid concurrent use of bacitracin with nonsteroidal antiinflammatory drugs.
Beclomethasone: Moderate Although some patients may need to be given corticosteroids and NSAIDs concomitantly, which can be done successfully for short periods of time without sequelae, prolonged concomitant administration should be avoided. Benazepril: Moderate In the low-renin or volume-dependent hypertensive patient, prostaglandins play an important role in the hypotensive effects of ACE inhibitors.
Benazepril; Hydrochlorothiazide, HCTZ: Moderate In the low-renin or volume-dependent hypertensive patient, prostaglandins play an important role in the hypotensive effects of ACE inhibitors. Bendroflumethiazide; Nadolol: Moderate If nonsteroidal anti-inflammatory drugs NSAIDs and an antihypertensive drug are concurrently used, carefully monitor the patient for signs and symptoms of renal insufficiency and blood pressure control.
Benzoic Acid; Hyoscyamine; Methenamine; Methylene Blue; Phenyl Salicylate: Major Concomitant use of analgesic doses of aspirin with ibuprofen is generally not recommended due to the increased risk of bleeding, including GI bleeding. Beta-blockers: Moderate If nonsteroidal anti-inflammatory drugs NSAIDs and an antihypertensive drug are concurrently used, carefully monitor the patient for signs and symptoms of renal insufficiency and blood pressure control.
Betamethasone: Moderate Although some patients may need to be given corticosteroids and NSAIDs concomitantly, which can be done successfully for short periods of time without sequelae, prolonged concomitant administration should be avoided. Betaxolol: Moderate If nonsteroidal anti-inflammatory drugs NSAIDs and an antihypertensive drug are concurrently used, carefully monitor the patient for signs and symptoms of renal insufficiency and blood pressure control. Betrixaban: Major Monitor patients closely and promptly evaluate any signs or symptoms of bleeding if betrixaban and nonsteroidal antiinflammatory drugs NSAIDs are used concomitantly.
Bexarotene: Major An increased risk of bleeding may occur when NSAIDs, such as ibuprofen, are used with agents that cause clinically significant thrombocytopenia, such as myelosuppressive antineoplastic agents.
Monitor closely for bleeding. Bictegravir; Emtricitabine; Tenofovir Alafenamide: Moderate Monitor for changes in serum creatinine and adverse reactions, such as lactic acidosis or hepatotoxicity if emtricitabine is administered in combination with nephrotoxic agents, such as high-dose nonsteroidal antiinflammatory drugs NSAIDs.
Consider the potential for drug interaction prior to and during concurrent use of these medications. Both emtricitabine and NSAIDs are excreted via the kidneys by a combination of glomerular filtration and active tubular secretion. While no drug interactions due to competition for renal excretion have been observed, coadministration of these medications may increase concentrations of both drugs.
Bismuth Subsalicylate: Major Concomitant use of analgesic doses of aspirin with ibuprofen is generally not recommended due to the increased risk of bleeding, including GI bleeding. Bismuth Subsalicylate; Metronidazole; Tetracycline: Major Concomitant use of analgesic doses of aspirin with ibuprofen is generally not recommended due to the increased risk of bleeding, including GI bleeding. Bisoprolol: Moderate If nonsteroidal anti-inflammatory drugs NSAIDs and an antihypertensive drug are concurrently used, carefully monitor the patient for signs and symptoms of renal insufficiency and blood pressure control.
Bisoprolol; Hydrochlorothiazide, HCTZ: Moderate If nonsteroidal anti-inflammatory drugs NSAIDs and an antihypertensive drug are concurrently used, carefully monitor the patient for signs and symptoms of renal insufficiency and blood pressure control.
Monitor for the presence of GI complaints, including potential GI ulceration and bleeding, as well as renal function, during combined use. Bisphosphonates may cause GI adverse events and occasionally, renal dysfunction. Though patients receiving intravenously administered bisphosphonates have a decreased incidence of GI adverse effects as compared to those taking orally administered bisphosphonates, nephrotoxicity is possible, and GI events are rarely reported.
Bivalirudin: Moderate An additive risk of bleeding may be seen in patients receiving anticoagulants in combination with other agents known to increase the risk of bleeding such as nonsteroidal antiinflammatory drugs NSAIDs. Bleomycin: Major An increased risk of bleeding may occur when NSAIDs, such as ibuprofen, are used with agents that cause clinically significant thrombocytopenia, such as myelosuppressive antineoplastic agents.
Brimonidine; Timolol: Moderate If nonsteroidal anti-inflammatory drugs NSAIDs and an antihypertensive drug are concurrently used, carefully monitor the patient for signs and symptoms of renal insufficiency and blood pressure control. Budesonide: Moderate Although some patients may need to be given corticosteroids and NSAIDs concomitantly, which can be done successfully for short periods of time without sequelae, prolonged concomitant administration should be avoided.
Budesonide; Formoterol: Moderate Although some patients may need to be given corticosteroids and NSAIDs concomitantly, which can be done successfully for short periods of time without sequelae, prolonged concomitant administration should be avoided. Budesonide; Glycopyrrolate; Formoterol: Moderate Although some patients may need to be given corticosteroids and NSAIDs concomitantly, which can be done successfully for short periods of time without sequelae, prolonged concomitant administration should be avoided.
Bumetanide: Moderate If a nonsteroidal anti-inflammatory drug NSAID and a diuretic are used concurrently, carefully monitor the patient for signs and symptoms of decreased renal function and diuretic efficacy.
Patients taking diuretics and NSAIDs concurrently are at higher risk of developing renal insufficiency. NSAIDs may reduce the natriuretic effect of diuretics in some patients. NSAIDs have been associated with an inhibition of prostaglandin synthesis, which may result in reduced renal blood flow leading to renal insufficiency and increases in blood pressure that are often accompanied by peripheral edema and weight gain.
Busulfan: Major Due to the thrombocytopenic effects of busulfan, an additive risk of bleeding may be seen in patients receiving concomitant anticoagulants, NSAIDs, platelet inhibitors, including aspirin, ASA, strontium chloride, and thrombolytic agents. Calcium Phosphate, Supersaturated: Moderate Concomitant use of medicines with potential to alter renal perfusion or function such as nonsteroidal anti-inflammatory drugs NSAIDs may increase the risk of acute phosphate nephropathy in patients taking sodium phosphate monobasic monohydrate; sodium phosphate dibasic anhydrous.
Calcium-channel blockers: Moderate If nonsteroidal anti-inflammatory drugs NSAIDs and an antihypertensive drug are concurrently used, carefully monitor the patient for signs and symptoms of renal insufficiency and blood pressure control. Cannabidiol: Moderate Consider a dose reduction of ibuprofen as clinically appropriate, if adverse reactions occur when administered with cannabidiol.
Increased ibuprofen exposure is possible. Ibuprofen is a CYP2C9 substrate. In vitro data predicts inhibition of CYP2C9 by cannabidiol potentially resulting in clinically significant interactions. Capecitabine: Moderate Monitor for an increase in ibuprofen-related adverse reactions e. Capreomycin: Major Because capreomycin is primarily eliminated by the kidney, coadministration with other potentially nephrotoxic drugs, including nonsteroidal antiinflammatory drugs NSAIDs , may increase serum concentrations of either drug.
Theoretically, the chronic coadministration of these drugs may increase the risk of developing nephrotoxicity, even in patients who have normal renal function.
Monitor patients for changes in renal function if these drugs are coadministered. Captopril: Moderate In the low-renin or volume-dependent hypertensive patient, prostaglandins play an important role in the hypotensive effects of ACE inhibitors.
Captopril; Hydrochlorothiazide, HCTZ: Moderate In the low-renin or volume-dependent hypertensive patient, prostaglandins play an important role in the hypotensive effects of ACE inhibitors.
Measure serum digoxin concentrations before initiating indomethacin. In addition, concomitant use of other nonsteroidal antiinflammatory drugs NSAIDs , including COX-2 inhibitors, with digoxin may result in increased serum concentrations of digoxin. Increased serum digoxin concentrations have been reported in patients who received digoxin and diclofenac sodium or ibuprofen. NSAIDs may cause a significant deterioration in renal function. A decline in glomerular filtration or tubular secretion may impair the excretion of digoxin.
Monitor patients during concomitant treatment for possible digoxin toxicity and reduce digoxin dose as necessary. Carmustine, BCNU: Major Due to the thrombocytopenic effects of carmustine, an additive risk of bleeding may be seen in patients receiving concomitant anticoagulants, NSAIDs, platelet inhibitors, including aspirin, ASA, strontium chloride, and thrombolytic agents.
These additive effects may not occur for at least 6 weeks after the administration of carmustine due to the delayed myelosuppressive effects of carmustine.
Carteolol: Moderate If nonsteroidal anti-inflammatory drugs NSAIDs and an antihypertensive drug are concurrently used, carefully monitor the patient for signs and symptoms of renal insufficiency and blood pressure control. Carvedilol: Moderate If nonsteroidal anti-inflammatory drugs NSAIDs and an antihypertensive drug are concurrently used, carefully monitor the patient for signs and symptoms of renal insufficiency and blood pressure control.
Cefotaxime: Minor Cefotaxime's product label states that cephalosporins may potentiate the adverse renal effects of nephrotoxic agents, such as aminoglycosides, nonsteroidal antiinflammatory drugs NSAIDs , and loop diuretics. Carefully monitor renal function, especially during prolonged therapy or use of high aminoglycoside doses.
The majority of reported cases involve the combination of aminoglycosides and cephalothin or cephaloridine, which are associated with dose-related nephrotoxicity as singular agents. Limited but conflicting data with other cephalosporins have been noted. Chlorambucil: Major Due to the thrombocytopenic effects of chlorambucil, an additive risk of bleeding may be seen in patients receiving concomitant anticoagulants, NSAIDs, platelet inhibitors, including aspirin, ASA, strontium chloride, and thrombolytic agents.
Chlorpropamide: Moderate NSAIDs may enhance hypoglycemia in diabetic patients via inhibition of prostaglandin synthesis, which indirectly increases insulin secretion. Chlorthalidone; Clonidine: Moderate If nonsteroidal anti-inflammatory drugs NSAIDs and an antihypertensive drug are concurrently used, carefully monitor the patient for signs and symptoms of renal insufficiency and blood pressure control.
Cholestyramine: Minor As with other nonsteroidal anti-inflammatory drugs NSAIDs , the absorption of ibuprofen can be delayed if cholestyramine is concomitantly administered.
Staggering the administration times may minimize this interaction. Choline Salicylate; Magnesium Salicylate: Major Concomitant use of analgesic doses of aspirin with ibuprofen is generally not recommended due to the increased risk of bleeding, including GI bleeding.
Cholinesterase inhibitors: Moderate NSAIDs may cause additive pharmacodynamic GI effects with cholinesterase inhibitors, leading to gastrointestinal intolerance. Ciclesonide: Moderate Although some patients may need to be given corticosteroids and NSAIDs concomitantly, which can be done successfully for short periods of time without sequelae, prolonged concomitant administration should be avoided.
Cidofovir: Contraindicated The concomitant administration of cidofovir and nonsteroidal antiinflammatory drugs NSAIDs is contraindicated due to the potential for increased nephrotoxicity. NSAIDs should be discontinued 7 days prior to beginning cidofovir. The manufacturer of clopidogrel advises that caution be used when used in combination with NSAIDs as an increase in occult GI blood loss occurred when clopidogrel was used concomitantly with naproxen Citalopram: Moderate The combined use of selective serotonin reuptake inhibitors SSRIs and nonsteroidal antiinflammatory drugs NSAIDs may increase the risk of bleeding, including an upper GI bleed.
Cladribine: Major Due to the thrombocytopenic effects of cladribine, an additive risk of bleeding may be seen in patients receiving concomitant anticoagulants, NSAIDs, platelet inhibitors, including aspirin, strontium chloride, and thrombolytic agents.
Clofarabine: Major Due to the thrombocytopenic effects of clofarabine, an additive risk of bleeding may be seen in patients receiving concomitant NSAIDs. Clonidine: Moderate If nonsteroidal anti-inflammatory drugs NSAIDs and an antihypertensive drug are concurrently used, carefully monitor the patient for signs and symptoms of renal insufficiency and blood pressure control.
The manufacturer of clopidogrel advises that caution be used when used in combination with NSAIDs as an increase in occult GI blood loss occurred when clopidogrel was used concomitantly with naproxen Colchicine; Probenecid: Major Probenecid can decrease the renal clearance of nonsteroidal antiinflammatory agents NSAIDs.
Colistimethate, Colistin, Polymyxin E: Major The administration of colistimethate sodium may increase the risk of developing nephrotoxicity, even in patients who have normal renal function.
Nonsteroidal antiinflammatory drugs NSAIDs may increase the risk for nephrotoxicity when used concurrently. Since colistimethate sodium is eliminated by the kidney, coadministration with other potentially nephrotoxic drugs, including nonsteroidal antiinflammatory drugs NSAIDs , may theoretically increase serum concentrations of either drug.
Conjugated Estrogens; Bazedoxifene: Moderate In clinical evaluation, a single dose of ibuprofen mg was given with a bazedoxifene 20 mg capsule in 12 postmenopausal women after an overnight fast.
The clinical effect of this change is not known. Use caution during coadministration and monitor patient closely. Corticosteroids: Moderate Although some patients may need to be given corticosteroids and NSAIDs concomitantly, which can be done successfully for short periods of time without sequelae, prolonged concomitant administration should be avoided. Cortisone: Moderate Although some patients may need to be given corticosteroids and NSAIDs concomitantly, which can be done successfully for short periods of time without sequelae, prolonged concomitant administration should be avoided.
Cyclosporine: Moderate Serum creatinine, potassium concentrations, and cyclosporine concentrations should be closely monitored when systemic cyclosporine is given with nonsteroidal antiinflammatory drugs NSAIDs. The effects of NSAIDs on the production of renal prostaglandins may cause changes in the elimination of cyclosporine.
Potentiation of renal dysfunction may especially occur in a dehydrated patient. Patients should be monitored for signs and symptoms of cyclosporine toxicity and infection, as NSAIDs may mask fever, pain, or swelling. Increased tear production was not seen in patients receiving ophthalmic NSAIDs or using punctual plugs concurrently with cyclosporine ophthalmic emulsion. Due to the thrombocytopenic effects of cytarabine, an additive risk of bleeding may be seen in patients receiving concomitant NSAIDs.
Dipyridamole can block membrane transport of cytarabine in tumor cells, therefore decreasing its antineoplastic activity. Dabigatran: Major Educate patients about the signs of increased bleeding and the need to report these signs to a healthcare provider immediately if coadministration of dabigatran and a nonsteroidal antiinflammatory drug NSAID is necessary. Dabigatran can cause significant and, sometimes, fatal bleeding.
Due to the thrombocytopenic effects of dacarbazine, an additive risk of bleeding may be seen in patients receiving concomitant anticoagulants, NSAIDs, platelet inhibitors, including aspirin, ASA, strontium chloride, and thrombolytic agents. Dactinomycin, Actinomycin D: Major An increased risk of bleeding may occur when NSAIDs are used with agents that cause clinically significant thrombocytopenia, such as myelosuppressive antineoplastic agents.
Dalteparin: Moderate An additive risk of bleeding may be seen in patients receiving anticoagulants in combination with other agents known to increase the risk of bleeding such as nonsteroidal antiinflammatory drugs NSAIDs.
Danaparoid: Moderate An additive risk of bleeding may be seen in patients receiving anticoagulants in combination with other agents known to increase the risk of bleeding such as nonsteroidal antiinflammatory drugs NSAIDs. Darunavir; Cobicistat; Emtricitabine; Tenofovir alafenamide: Moderate Monitor for changes in serum creatinine and adverse reactions, such as lactic acidosis or hepatotoxicity if emtricitabine is administered in combination with nephrotoxic agents, such as high-dose nonsteroidal antiinflammatory drugs NSAIDs.
Dasatinib: Major Due to the thrombocytopenic and possible platelet inhibiting effects of dasatinib, an additive risk of bleeding may be seen in patients receiving concomitant anticoagulants, NSAIDs, platelet inhibitors including aspirin , strontium chloride, and thrombolytic agents. Caution should be exercised if patients are required to take medications that inhibit platelet function or anticoagulants concomitantly with dasatinib.
Deferasirox: Moderate Because gastric ulceration and GI bleeding have been reported in patients taking deferasirox, use caution when coadministering with other drugs known to increase the risk of peptic ulcers or gastric hemorrhage including NSAIDs.
In addition, coadministration of deferasirox with other potentially nephrotoxic drugs, including NSAIDs, may increase the acute renal failure. Denileukin Diftitox: Major An increased risk of bleeding may occur when NSAIDs, such as ibuprofen, are used with agents that cause clinically significant thrombocytopenia, such as myelosuppressive antineoplastic agents. Desirudin: Moderate An additive risk of bleeding may be seen in patients receiving anticoagulants in combination with other agents known to increase the risk of bleeding such as nonsteroidal antiinflammatory drugs NSAIDs.
Desmopressin: Major Additive hyponatremic effects may be seen in patients treated with desmopressin and drugs associated with hyponatremia including NSAIDs.
Use combination with caution, and monitor patients for signs and symptoms of hyponatremia. A woman who took both desmopressin and ibuprofen was found in a comatose state. The woman had previously received desmopressin without the development of clinical symptoms of hyponatremia Desvenlafaxine: Moderate Platelet aggregation may be impaired by desvenlafaxine due to platelet serotonin depletion, possibly increasing the risk of a bleeding complication e.
Patients should be monitored for signs and symptoms of bleeding while taking desvenlafaxine with NSAIDs. Dexamethasone: Moderate Although some patients may need to be given corticosteroids and NSAIDs concomitantly, which can be done successfully for short periods of time without sequelae, prolonged concomitant administration should be avoided.
Diazoxide: Moderate If nonsteroidal anti-inflammatory drugs NSAIDs and an antihypertensive drug are concurrently used, carefully monitor the patient for signs and symptoms of renal insufficiency and blood pressure control. Dichlorphenamide: Moderate Use dichlorphenamide and ibuprofen together with caution as both drugs can cause metabolic acidosis.
Concurrent use may increase the severity of metabolic acidosis. Measure sodium bicarbonate concentrations at baseline and periodically during dichlorphenamide treatment. If metabolic acidosis occurs or persists, consider reducing the dose or discontinuing dichlorphenamide therapy.
The manufacturer of clopidogrel advises that caution be used when used in combination with NSAIDs as an increase in occult GI blood loss occurred when clopidogrel was used concomitantly with naproxen Docetaxel: Major Due to the thrombocytopenic effects of docetaxel, an additive risk of bleeding may be seen in patients receiving concomitant anticoagulants, NSAIDs, platelet inhibitors including aspirin , strontium chloride, and thrombolytic agents. Cases of acute renal failure, some requiring hospitalization and renal replacement therapy, have been reported after high-dose or multiple NSAIDs were initiated in patients who appeared stable on tenofovir.
If these drugs must be coadministered, carefully monitor the estimated creatinine creatinine, serum phosphorus, urine glucose, and urine protein prior to, and periodically during, treatment.
Dorzolamide; Timolol: Moderate If nonsteroidal anti-inflammatory drugs NSAIDs and an antihypertensive drug are concurrently used, carefully monitor the patient for signs and symptoms of renal insufficiency and blood pressure control. Doxazosin: Moderate If nonsteroidal anti-inflammatory drugs NSAIDs and an antihypertensive drug are concurrently used, carefully monitor the patient for signs and symptoms of renal insufficiency and blood pressure control.
Drospirenone: Minor Drospirenone has antimineralocorticoid effects; the progestin may increase serum potassium. Other drugs that may have additive effects on serum potassium with drospirenone include chronic treatment with NSAIDs, and monitoring of serum potassium in the 1st month of concurrent therapy is recommended.
Drospirenone; Estetrol: Minor Drospirenone has antimineralocorticoid effects; the progestin may increase serum potassium. Drospirenone; Estradiol: Minor Drospirenone has antimineralocorticoid effects; the progestin may increase serum potassium.
Drospirenone; Ethinyl Estradiol: Minor Drospirenone has antimineralocorticoid effects; the progestin may increase serum potassium. Drospirenone; Ethinyl Estradiol; Levomefolate: Minor Drospirenone has antimineralocorticoid effects; the progestin may increase serum potassium.
Minor L-methylfolate should be used cautiously in patients taking high doses of ibuprofen. Plasma concentrations of L-methylfolate may be reduced when used concomitantly with high doses of ibuprofen. Monitor patients for decreased efficacy of L-methylfolate if these agents are used together. These patients are at increased risk of bleeding during drotrecogin alfa therapy. Advil Tablets. Advil Dual Action. Combining Medications.
Pre-existing Health Conditions. Relief Finder. Advil Migraine Control your migraines before they control you. Treats migraines. If symptoms persist or worsen, ask your doctor. Do not take more than 2 capsules in 24 hours unless directed by a doctor. Under 18 years of age: Ask a doctor. Read complete warnings and information. View full product labeling. View the complete Advil family of products. Follow Us.
0コメント